Related Experiment Videos
Substrate-labeled fluorescent immunoassay for amikacin in human serum
Antimicrobial Agents and Chemotherapy
|August 1, 1980
Summary
A new fluorescent immunoassay accurately measures amikacin in human serum using only 2 microliters. This method offers a rapid and simple alternative to radioimmunoassay for determining amikacin drug levels.
Area of Science:
- Biochemistry
- Analytical Chemistry
- Pharmacology
Background:
- Amikacin is a crucial antibiotic requiring therapeutic drug monitoring.
- Existing methods like radioimmunoassay can be complex and time-consuming.
Purpose of the Study:
- To develop a novel, rapid, and sensitive fluorescent immunoassay for quantifying amikacin in human serum.
- To validate the assay's performance against established methods.
Main Methods:
- A homogeneous substrate-labeled fluorescent immunoassay was developed.
- Amikacin was covalently labeled with beta-galactosyl-umbelliferone.
- Competition between labeled and unlabeled amikacin for antibody binding was utilized.
Main Results:
- The assay demonstrated high correlation (r = 0.987) with radioimmunoassay results.
- The assay is rapid, simple, and requires only 2 microliters of serum.
- Fluorescence intensity is directly proportional to unlabeled amikacin concentration.
Conclusions:
- The developed fluorescent immunoassay is a viable and efficient method for therapeutic drug monitoring of amikacin.
- This assay offers advantages in speed, simplicity, and sample volume compared to traditional methods.